{
    "root": "3633ef65-d53d-4728-e063-6394a90a6205",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250528",
    "ingredients": [
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B"
        }
    ],
    "indications": "ondansetron oral solution indicated prevention nausea vomiting associated : highly emetogenic cancer chemotherapy , including cisplatin greater equal 50 mg/m 2. initial repeat courses moderately emetogenic cancer chemotherapy . radiotherapy patients receiving either total body irradiation , single high-dose fraction abdomen , daily fractions abdomen .",
    "contraindications": "full prescribing information recommended adults pediatrics . ( 2 ) patients severe hepatic impairment : exceed total daily dose 8 mg. ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "product : 17856-0691 ndc : 17856-0691-5 5 ml cup ndc : 17856-0691-1 1.5 ml syringe ndc : 17856-0691-2 2.5 ml syringe , plastic",
    "adverseReactions": "ondansetron contraindicated patients : known hypersensitivity ( e.g . , anaphylaxis ) ondansetron components formulation [ ( 6.2 ) ] . receiving concomitant apomorphine due risk profound hypotension loss consciousness .",
    "indications_original": "Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with:\n                  \n                     highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m\n  \n   2.\n \n  \n                     initial and repeat courses of moderately emetogenic cancer chemotherapy.\n                     radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.",
    "contraindications_original": "See full prescribing information for the recommended dosage in adults and pediatrics. (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. (2.2, 8.6)",
    "warningsAndPrecautions_original": "Product: 17856-0691\n                  NDC: 17856-0691-5 5 mL in a CUP\n                  NDC: 17856-0691-1 1.5 mL in a SYRINGE\n                  NDC: 17856-0691-2 2.5 mL in a SYRINGE, PLASTIC",
    "adverseReactions_original": "Ondansetron is contraindicated in patients:\n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation\n  \n   [see\n   \n    Adverse Reactions (6.2)].\n  \n   \n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness."
}